Academia

Systematic review maps 410 lymphoma antibody drug conjugates clinical trials, revealing limited diversity beyond MMAE, few survival end points, and scarce biomarkers in DLBCL and classical Hodgkin lymphoma.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.

As drug research globalizes, regulators and trial designers must collaborate across regions to bring new treatments to patients.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

Attempts to refine non–small cell lung cancer treatment selection have been limited by a lack of biomarkers, but recent research is expanding the potential landscape.

Dual inhibition of BIRC5 and MCL-1 showed strong synergistic activity in preclinical models of MCL.

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly elevated incidence rates and has strong willingness to participate in prevention trials.

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma.

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and multidisciplinary approaches have improved outcomes, improving quality of life.

How strategic partnerships in oncology can enhance patient care by addressing diverse needs through collaboration.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.

One-third of F32 grant recipients secure follow-up NIH K awards, fueling new biomedical discoveries and career growth.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

Metallomic correlations suggest environmental and metabolic metals act together to accelerate renal damage.

Integrated data suggest higher tryptophan activity is associated with reduced inflammation and improved outcomes in RA.

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.